For research use only, not for therapeutic use.
Edatrexate (Cat.No:I006589) is a polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated. Check for active clinical trials or closed clinical trials using this agent.
| Catalog Number | I006589 |
| CAS Number | 80576-83-6 |
| Synonyms | 10-ethyldeazaaminopterin; 10-EDAM; CGP30694; CGP 30694; Edatrexate.;(2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid |
| Molecular Formula | C22H25N7O5 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid |
| InChI | InChI=1S/C22H25N7O5/c1-2-11(9-14-10-25-19-17(26-14)18(23)28-22(24)29-19)12-3-5-13(6-4-12)20(32)27-15(21(33)34)7-8-16(30)31/h3-6,10-11,15H,2,7-9H2,1H3,(H,27,32)(H,30,31)(H,33,34)(H4,23,24,25,28,29)/t11?,15-/m0/s1 |
| InChIKey | FSIRXIHZBIXHKT-MHTVFEQDSA-N |
| SMILES | CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O |
| Reference | </br>1:Evaluation of dose-intense Ifosfamide, with and without edatrexate, in adults with sarcoma. Casper ES, Schwartz GM, Leung D, Sugarman A, Bertino JR.Sarcoma. 1999;3(2):121-7. doi: 10.1080/13577149977758. PMID: 18521274 Free PMC Article</br>2:Phase I trial of edatrexate in advanced breast and other cancers. Kuriakose P, Gandara DR, Perez EA.Cancer Invest. 2002;20(4):473-9. PMID: 12094542 </br>3:A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial. Colon-Otero G, Niedringhaus RD, Hillman SH, Geyer S, Sloan J, Krook JE, Windschitl HE, Marks RS, Wiesenfeld M, Tschetter LK, Jett JJ; North Central Cancer Treatment Group..Am J Clin Oncol. 2001 Dec;24(6):551-5. PMID: 11801752 </br>4:Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin. Laurie SA, Pfister DG, Kris MG, Tong WP, Chronowski G, Pisters KM, Heelan RT, Sirotnak FM.Clin Cancer Res. 2001 Mar;7(3):501-9. PMID: 11297240 Free Article</br>5:Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Kindler HL, Belani CP, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR.Cancer. 1999 Nov 15;86(10):1985-91. PMID: 10570422 </br>6:Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). Meyers FJ, Lew D, Lara PN Jr, Williamson S, Marshall E, Balcerzak SP, Rivkin SE, Samlowski W, Crawford ED.Invest New Drugs. 1998-1999;16(4):347-51. PMID: 10426670 </br>7:Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Rigas JR, Kris MG, Miller VA, Pisters KM, Heelan RT, Grant SC, Fennelly DW, Chou TC, Sirotnak FM.Ann Oncol. 1999 May;10(5):601-3. PMID: 10416013 </br>8:Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer. D/’Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.Clin Cancer Res. 1999 Feb;5(2):275-9. PMID: 10037175 Free Article</br>9:Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. Edelman MJ, Gandara DR, Perez EA, Lau D, Lauder I, Turrell C, Uhrich M, Meyers F.Invest New Drugs. 1998;16(1):69-75. PMID: 9740546 </br>10:A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G, Marschke R, Camoriano JK, Sorensen JM, Sloan JA, Richardson RL.Cancer J Sci Am. 1997 Sep-Oct;3(5):297-302. PMID: 9327154 |
